US 12,281,161 B2
Polypeptides and uses thereof
Mark Grinstaff, Brookline, MA (US); Aladin Hamoud, Brookline, MA (US); Samantha Berry, Brighton, MA (US); Christopher Gromisch, Hamden, CT (US); and Alina Ringaci, Allston, MA (US)
Assigned to TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US)
Filed by TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US)
Filed on Jul. 26, 2022, as Appl. No. 17/873,864.
Claims priority of provisional application 63/226,457, filed on Jul. 28, 2021.
Prior Publication US 2023/0125881 A1, Apr. 27, 2023
Int. Cl. A61K 47/65 (2017.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01)
CPC C07K 16/28 (2013.01) [A61K 47/65 (2017.08); A61K 47/68031 (2023.08); A61K 47/6849 (2017.08); C07K 16/2863 (2013.01); C07K 2317/24 (2013.01); C07K 2319/30 (2013.01)] 23 Claims
 
1. An antibody, wherein a polypeptide chain of the antibody is linked on its C-terminus to a coiled-coil peptide, wherein the coiled-coil peptide is capable of forming a heterodimer with another coiled-coil peptide and comprises the amino acid sequence selected from the group consisting of:
SPEDEIQQLEEEIAQLEQKNAALKEKNQALKYGKG (SEQ ID NO: 10);
SPEDKIAQLKEK NAALKEKNQQLKEKLQALKYG (SEQ ID NO: 11);
SPEDEIQQLEEEIAQLEQKNAALKEKNQALKYG (SEQ ID NO: 12);
SPEDKIAQLKQKIQALKQENQQLEEENAALEYG (SEQ ID NO: 13);
MK LKKIKSV LKKIKSV LKKIKSV LKKIKSV VGER (SEQ ID NO: 1);
LKKIKSV LKKIKSV LKKIKSV LKKIKSV (SEQ ID NO: 5);
LKKIKSV LKKIKSV LKKIKKV LKKIKYV (SEQ ID NO: 6);
LEEIVSE LEEIVSE LEEIVSE LEEIVSE (SEQ ID NO: 7); or
LEEIVSE LEEIVSE LEEIVKE LEEIVYE (SEQ ID NO: 8), and
wherein the antibody further comprises a second coiled-coil peptide forming a heterodimer with the coiled-coil peptide linked to the polypeptide chain of the antibody, and wherein the second coiled-coil peptide comprises the amino acid sequence SPEDEIQALEEENAQLEQENAALEEELAQLEYGK-azidoG (SEQ ID NO: 4); MK-LEEIVSE-LEEIVSE-LEEIV(X1)E-LEEIVYE-VGER (SEQ ID NO: 51), where X1 is lysine linked at N-ε position with —X2-L, where X2 is a linker and L is a ligand; or SPEDEIQALEEENAQLEQENAALEEE LAQLEYG(X1)KG (SEQ ID NO: 52), where X1 is lysine linked at N-ε position with —X2-L, where X2 is a linker and L is a ligand.